Antioxidant and hypoglycemic effects of watercress (Nasturtium officinale) extracts in diabetic rats

Background: Watercress is a semi-aquatic plant used in traditional medicine to treat various ailments, such as flu, cough, avitaminosis, and anorexia; it is also used as a diuretic and for hypoglycemia treatment in diabetes. In this study, we report the antioxidant and hypoglycemic activity of orally administered aqueous (WAQE), acetonic (WAE), and alcoholic (WOHE) watercress extracts. The effect of subchronic administration of watercress extracts on oxidative stress was also studied.Materials and Methods: WAQE, WAE, and WOHE were obtained and administered orally. Alloxan (200 mg/kg) and streptozotocin (60 mg/kg) were applied to induce hyperglycemia in male Wistar rats. Phenolic and flavonoid content, as well as antioxidant activity of the extracts were measured. The acute and subchronic effects (8 weeks) of WAQE were evaluated. The activity of antioxidant enzymes levels of malondialdehyde, hepatic enzyme markers in the serum, and renal function markers, were assessed. Histopathological evaluation of the pancreas, kidney, and liver was performed using hematoxylin-eosin staining.Results: Watercress extracts have high concentrations of phenols, polyphenols, and flavonoids, in addition to a very high antioxidant effect. The hypoglycemic effect of WAQE upon acute administration was 76.6% higher than that of insulin. When administered chronically, glucose levels were normalized on the third week up to the eighth week. Furthermore, the antioxidant enzymes and biochemical parameters improved.Conclusion: WAQE administration to diabetic rats reduced oxidative stress damage and decreased glucose levels. This study supports the use of this plant for the treatment of diabetes.Keywords: Antioxidant, Diabetes, Watercress (Nasturtium officinale), Oxidative stress, Pancrea

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362